Analyzing Cost of Revenue: Pfizer Inc. and Biogen Inc.

Analyzing Cost of Revenue: Pfizer Inc. vs. Biogen Inc.

In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for evaluating a company's financial health. From 2014 to 2023, Pfizer Inc. and Biogen Inc. have shown distinct trends in their cost of revenue. Pfizer's cost of revenue surged by approximately 210% from 2014 to 2023, peaking in 2022. This reflects its aggressive expansion and investment in new drug development. In contrast, Biogen's cost of revenue increased by about 116% over the same period, indicating a more steady growth trajectory.

The year 2021 marked a significant leap for Pfizer, with a 250% increase compared to 2020, likely due to its COVID-19 vaccine production. Meanwhile, Biogen's cost of revenue grew consistently, with a notable 20% rise in 2023. These insights highlight the strategic differences between the two giants, offering a glimpse into their operational priorities and market strategies.